Progenitor, Inc.
Records under this name other than patents Progenitor, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 6,228,594 | Method for determining the presence or absence of a hereditary hemochromatosis gene mutation Formerly held Term ended Term ended Feb 14, 2020 · From the USPTO record | Term ended | Term ended Feb 14, 2020 | From the USPTO record |
| US 6,284,732 | Peptides and peptide analogues designed from HFE protein and their uses in the treatment of iron overload diseases Formerly held Term ended Term ended Dec 18, 2018 · From the USPTO record | Term ended | Term ended Dec 18, 2018 | From the USPTO record |
| US 6,391,852 | Methods and compositions for diagnosis and treatment of iron overload diseases and iron deficiency diseases Formerly held Term ended Term ended Jun 13, 2017 · From the USPTO record | Term ended | Term ended Jun 13, 2017 | From the USPTO record |
| US 6,140,305 | Hereditary hemochromatosis gene products Formerly held Term ended Term ended Apr 4, 2017 · From the USPTO record | Term ended | Term ended Apr 4, 2017 | From the USPTO record |
| US 6,025,130 | Hereditary hemochromatosis gene Formerly held Term ended Term ended May 23, 2016 · From the USPTO record | Term ended | Term ended May 23, 2016 | From the USPTO record |
| US 6,849,399 | Methods and compositions for diagnosis and treatment of iron misregulation diseases Formerly held Term ended Ended no later than May 23, 2016 · From the USPTO record | Term ended | Ended no later than May 23, 2016 | From the USPTO record |
| US 7,026,116 | Polymorphisms in the region of the human hemochromatosis gene Formerly held Term ended Term ended Apr 4, 2016 · From the USPTO record | Term ended | Term ended Apr 4, 2016 | From the USPTO record |
| US 7,078,513 | Plasmids comprising nucleic acids from the hereditary hemochromatosis gene Formerly held Term ended Ended no later than Apr 4, 2016 · From the USPTO record | Term ended | Ended no later than Apr 4, 2016 | From the USPTO record |
| US 6,355,237 | Methods for using the obese gene and its gene product to stimulate hematopoietic development Formerly held Term ended Term ended Sep 14, 2014 · From the USPTO record | Term ended | Term ended Sep 14, 2014 | From the USPTO record |
| US 6,670,321 | Prevention and treatment for retinal ischemia and edema Formerly held Lapsed on the fee record Ended Dec 30, 2011 · From the USPTO record | Lapsed on the fee record | Ended Dec 30, 2011 | From the USPTO record |